Emerging Systemic Therapies for Colorectal Cancer
- PMID: 29720904
- PMCID: PMC5929883
- DOI: 10.1055/s-0037-1602238
Emerging Systemic Therapies for Colorectal Cancer
Abstract
Despite advances over the past 20 years in colorectal cancer (CRC) screening, diagnosis, and treatment, survival outcomes remain suboptimal. Five-year survival for patients with locally advanced CRC is 69%; 5-year survival drops to 12% for patients with metastatic disease. Novel, effective systemic therapies are needed to improve long-term outcomes. In this review, we describe currently available systemic therapies for the treatment of locally advanced and metastatic CRC and discuss emerging therapies, including encouraging advances in identifying novel targeted agents and exciting responses to immunotherapeutic agents.
Keywords: clinical trials; colorectal cancer; emerging therapies; immunotherapy; targeted therapy.
Figures
Similar articles
-
Overview of resistance to systemic therapy in patients with breast cancer.Adv Exp Med Biol. 2007;608:1-22. doi: 10.1007/978-0-387-74039-3_1. Adv Exp Med Biol. 2007. PMID: 17993229 Review.
-
Colorectal Cancer Liver Metastasis: Evolving Paradigms and Future Directions.Cell Mol Gastroenterol Hepatol. 2017 Jan 20;3(2):163-173. doi: 10.1016/j.jcmgh.2017.01.006. eCollection 2017 Mar. Cell Mol Gastroenterol Hepatol. 2017. PMID: 28275683 Free PMC article. Review.
-
Role of transmembrane glycoprotein mucin 1 (MUC1) in various types of colorectal cancer and therapies: Current research status and updates.Biomed Pharmacother. 2018 Nov;107:1318-1325. doi: 10.1016/j.biopha.2018.08.109. Epub 2018 Aug 29. Biomed Pharmacother. 2018. PMID: 30257347 Review.
-
Updates on immunotherapy for colorectal cancer.J Gastrointest Oncol. 2018 Feb;9(1):160-169. doi: 10.21037/jgo.2018.01.17. J Gastrointest Oncol. 2018. PMID: 29564182 Free PMC article. Review.
-
Immunotherapy in human colorectal cancer: Challenges and prospective.World J Gastroenterol. 2016 Jul 28;22(28):6362-72. doi: 10.3748/wjg.v22.i28.6362. World J Gastroenterol. 2016. PMID: 27605872 Free PMC article. Review.
Cited by
-
MicroRNAs and drug resistance in colorectal cancer with special focus on 5-fluorouracil.Mol Biol Rep. 2022 Jun;49(6):5165-5178. doi: 10.1007/s11033-022-07227-1. Epub 2022 Feb 25. Mol Biol Rep. 2022. PMID: 35212928 Review.
-
The Long Noncoding RNA, LINC01555, Promotes Invasion and Metastasis of Colorectal Cancer by Activating the Neuropeptide, Neuromedin U.Med Sci Monit. 2019 May 30;25:4014-4024. doi: 10.12659/MSM.916508. Med Sci Monit. 2019. PMID: 31144675 Free PMC article.
-
Thymidylate Synthase Overexpression Drives the Invasive Phenotype in Colon Cancer Cells.Biomedicines. 2022 May 29;10(6):1267. doi: 10.3390/biomedicines10061267. Biomedicines. 2022. PMID: 35740289 Free PMC article.
-
Extracellular vesicles derived from Lactobacillus plantarum restore chemosensitivity through the PDK2-mediated glucose metabolic pathway in 5-FU-resistant colorectal cancer cells.J Microbiol. 2022 Jul;60(7):735-745. doi: 10.1007/s12275-022-2201-1. Epub 2022 Jul 4. J Microbiol. 2022. PMID: 35781627
-
Unveiling the genetic and epigenetic landscape of colorectal cancer: new insights into pathogenic pathways.Med Oncol. 2023 Oct 19;40(11):334. doi: 10.1007/s12032-023-02201-8. Med Oncol. 2023. PMID: 37855910 Review.
References
-
- Siegel R L, Miller K D, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(01):7–30. - PubMed
-
- American Cancer Society.Cancer Facts & Figures 2016Atlanta: American Cancer Society;2016. Available at:http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2.... Accessed March 18, 2016
-
- André T, Boni C, Navarro M et al.Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109–3116. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous